血浆置换治疗抗中性粒细胞胞质抗体相关性血管炎所致严重肺泡出血:一项目标试验模拟研究
本研究利用全国多中心回顾性队列数据,模拟目标试验,评估血浆置换对严重ANCA相关性血管炎相关弥漫性肺泡出血患者死亡率的影响。共纳入184例患者,其中144例(78.3%)接受血浆置换,40例(21.7%)未接受。主要终点为ICU入住后30天死亡率,采用Cox模型校正预设混杂因素。结果显示,血浆置换组30天生存率为85%(95%CI 81-90),未血浆置换组为88%(95%CI 77-96),风险比1.23(95%CI 0.57-3.89),无显著差异。次要结局亦相似。结论认为,血浆置换未降低此类患者的30天死亡率。
要点
- 在严重AAV相关DAH患者中,血浆置换组30天生存率85%(95%CI 81-90),未血浆置换组88%(95%CI 77-96),HR 1.23(95%CI 0.57-3.89),无显著差异。
- 研究纳入184例患者,血浆置换组144例(78.3%),未血浆置换组40例(21.7%);两组基线特征相似,但血浆置换组肾功能损害更严重(肌酐357 vs 171 µmol/L,P=0.01)且环磷酰胺使用更频繁(77% vs 55%,P=0.01)。
- ICU入住时疾病严重程度(中位SAPS II评分42)和机械通气需求(54%)在两组间相当。
- 次要结局在两组间亦相似。
- 该研究为模拟目标试验,采用回顾性多中心队列数据,校正预设混杂因素后未发现血浆置换降低30天死亡率。
适用人群与场景
- 严重ANCA相关性血管炎相关弥漫性肺泡出血患者,来自全国多中心回顾性队列,纳入ICU治疗的患者。
研究设计与关键结果
- 研究类型:模拟目标试验,使用全国多中心回顾性队列数据。
- 样本量:184例患者;中位年龄66(53-75)岁;51%女性;51%为肉芽肿性多血管炎;53% MPO-ANCA阳性。
- 干预与对照:144例(78.3%)接受血浆置换,40例(21.7%)未接受。
- 主要终点:30天死亡率(ICU入住后),采用Cox模型校正预设混杂因素;血浆置换组30天生存率85%(95%CI 81-90) vs 未血浆置换组88%(95%CI 77-96),HR 1.23(95%CI 0.57-3.89)。
证据类型、等级与局限
- 证据类型:模拟目标试验,基于回顾性多中心队列数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:在模拟目标试验中,血浆置换未降低严重AAV相关DAH患者的30天死亡率。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Patients with severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-related diffuse alveolar hemorrhage (DAH) face high mortality. In the PEXIVAS trial, plasma exchange (PLEX) did not reduce death or end-stage kidney disease, but only 9% had severe DAH.
OBJECTIVES: This study aimed to assess whether PLEX lowers mortality in patients with severe DAH.
METHODS: We emulated a target trial using retrospective data from a national multicenter cohort of patients with severe AAV-related DAH. The primary endpoint was 30-day mortality after intensive care unit (ICU) admission, analyzed using a Cox model adjusted for prespecified confounders.
MEASUREMENTS AND MAIN RESULTS: We included 184 patients (median age 66 [53-75] years; 51% female; 51% with granulomatosis with polyangiitis; 53% MPO (Myeloperoxydase)-ANCA positive). Of these, 144 (78.3%) received PLEX, and 40 (21.7%) did not. Baseline characteristics were similar, except for more severe renal impairment (creatinine 357 vs 171 µmol/L, P = .01) and more frequent cyclophosphamide use (77% vs 55%, P = .01) in the PLEX group. Severity at ICU admission (median Simplified Acute Physiology Score II score: 42) and mechanical ventilation needs (54%) were comparable between groups. At 30 days, overall survival was 85%. No significant difference in mortality was observed between the PLEX and no-PLEX groups: 30-day survival was 85% (95% CI, 81-90) with PLEX vs 88% (95% CI, 77-96) without (hazard ratio, 1.23; 95% CI, 0.57-3.89). Secondary outcomes were also similar.
CONCLUSIONS: In this emulated target trial, PLEX did not reduce 30-day mortality in patients with severe AAV-related DAH.
参考来源
- Sanna AC, Gendreau S, Desnos C, et al. Plasma exchange for severe alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: emulation of a target trial. Am J Respir Crit Care Med. 2026. PMID: 41738152. doi:10.1093/ajrccm/aamaf122
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。